The Framingham Heart Study is a long term prospective study of the etiology of cardiovascular disease among a population of non-institutionalized people in the community of Framingham, Massachusetts. The Framingham Heart Study was a landmark study in epidemiology in that it was the first prospective study of cardiovascular disease and identified the concept of risk factors and their joint effects. The study began in 1956 and 5,209 subjects were initially enrolled in the study. In our dataset, we included variables from the first examination in 1956 and the third examination, in 1968. Clinic examination data has included cardiovascular disease risk factors and markers of disease such as blood pressure, blood chemistry, lung function, smoking history, health behaviors, ECG tracings, echocardiography, and medication use. Through regular surveillance of area hospitals, participant contact, and death certificates, the Framingham Heart Study reviews and adjudicates events for the occurrence of any of the following types of coronary heart disease(CHD): angina pectoris, myocardial infarction, heart failure, and cerebrovascular disease.
FraminghamA data frame with 400 rows and 33 variables:
case number
sex
serum cholesterol (mg/dL) at initial examination
age (years) at initial examination
systolic blood pressure (mmHg) at initial examination
diastolic blood pressure (mmHg) at initial examination
indicator that participant currently is a cigarette smoker at initial examination
cigarettes smoked per day at initial examination
Body Mass Index (kg/(M*M)) at initial examination
indicator that participant is diabetic at initial examination
use of anti-hypertensive medication at initial examination
ventricular rate (beats/min) at initial examination
casual glucose (mg/dL) at initial examination
prevalent CHD (angina pectoris, myocardial infarction, or coronary insufficiency) at initial examination
days since initial examination
days from initial examination to any CHD event
serum cholesterol (mg/dL) at third examination
age (years) at third examination
systolic blood pressure (mmHg) at third examination
diastolic blood pressure (mmHg) at third examination
indicator that participant currently is a cigarette smoker at third examination
cigarettes smoked per day at third examination
Body Mass Index (kg/(M*M) at third examination
indicator that participant is diabetic at third examination
use of anti-hypertensive medication at third examination
ventricular rate (beats/min) at third examination
casual glucose (mg/dL) at third examination
prevalent CHD (angina pectoris, myocardial infarction, or coronary insufficiency) at third examination
days since initial examination at third examination
HDL cholesterol (mg/dL) at third examination
LDL cholesterol (mg/dL) at third examination
days from initial examination to any CHD event at third examination
indicator of event of hospitalized myocardial infarction, angina pectoris, coronary insufficiency, or fatal CHD by the end of the study
The associated dataset is a subset of the data collected as part of the Framingham study and includes laboratory, clinic, questionnaire, and adjudicated event data on 400 participants. These participants for the dataset have been chosen so that among all male participants, 100 smokers and 100 non-smokers were selected at random. A similar procedure resulted in 100 female smokers and 100 female non-smokers. This procedure resulted in an over-sampling of smokers. The data for each participant is on one row. People who had any type of CHD in the initial examination period are not included in the dataset.